Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla furthers Lilly's commitment to expanding access to innovative treatments for chronic conditions," said Winselow Tucker, President and General Manager, Lilly India.

"Our mission-to make life better for people around the world-drives our commitment to accelerate the introduction of innovative medicines and expand access to hard-to-reach communities. With India facing a growing burden of type 2 diabetes and obesity, broader availability of Tirzepatide will ensure that more patients can benefit from this innovative therapy," he added.

Lilly will manufacture and supply Yurpeak to Cipla, while Cipla will distribute and pr...